Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Nov;8(5):407-19.
doi: 10.1016/j.ccr.2005.10.013.

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Dharminder Chauhan  1 , Laurence Catley, Guilan Li, Klaus Podar, Teru Hideshima, Mugdha Velankar, Constantine Mitsiades, Nicolas Mitsiades, Hiroshi Yasui, Anthony Letai, Huib Ovaa, Celia Berkers, Benjamin Nicholson, Ta-Hsiang Chao, Saskia T C Neuteboom, Paul Richardson, Michael A Palladino, Kenneth C Anderson
Affiliations
Free article
Comparative Study

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Dharminder Chauhan et al. Cancer Cell. 2005 Nov.
Free article

Abstract

Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); however, prolonged treatment is associated with toxicity and development of drug resistance. Here, we show that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and Bortezomib therapies. NPI-0052 is distinct from Bortezomib in its chemical structure, effects on proteasome activities, mechanisms of action, and toxicity profile against normal cells. Moreover, NPI-0052 is orally bioactive. In animal tumor model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumor recurrence. Combining NPI-0052 and Bortezomib induces synergistic anti-MM activity. Our study therefore provides the rationale for clinical protocols evaluating NPI-0052, alone and together with Bortezomib, to improve patient outcome in MM.

PubMed Disclaimer

Publication types

MeSH terms